Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
-
Published:2020-06
Issue:
Volume:132
Page:61-70
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Maillet Denis,
Corbaux Pauline,
Stelmes Jean-JacquesORCID,
Dalle Stéphane,
Locatelli-Sanchez Myriam,
Perier-Muzet Marie,
Duruisseaux Michaël,
Kiakouama-Maleka Lize,
Freyer Gilles,
Boespflug Amélie,
Péron Julien
Subject
Cancer Research,Oncology
Reference34 articles.
1. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet (London, England),2019
2. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up;Fradet;Ann Oncol,2019
3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015
4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015
5. The significance of the PD-L1 expression in non-small-cell lung cancer: trenchant double swords as predictive and prognostic markers;Takada;Clin Lung Cancer,2018
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献